Treatment of gastric leaks after Roux-en-Y gastric bypass: a paradigm shift

Surg Obes Relat Dis. 2013 Mar-Apr;9(2):229-33. doi: 10.1016/j.soard.2012.01.006. Epub 2012 Jan 16.

Abstract

Background: During the past decade, nonoperative treatment of leaks after bariatric surgery has been deemed acceptable in selected patients. The setting of our study was 2 university affiliated hospitals.

Methods: We reviewed gastric leaks in 1069 consecutive bariatric operations that were performed by 1 surgeon during the past 8 years, including 836 primary laparoscopic Roux-en-Y gastric bypass (RYGB), 114 primary open RYGBs, and 119 revisional procedures. Drains were used routinely in the laparoscopic and revision groups and selectively in the open group. Perforations and jejunojejunostomy leaks were excluded.

Results: There were no leaks after open RYGB, 8 leaks (.95%) after laparoscopic RYGB, and 5 leaks (4.2%) after the revisional procedures. Of the 13 leaks, 7 occurred at the gastrojejunostomy, 6 at the staple line of the upper pouch, and none in the excluded stomach. Of the 8 postlaparoscopic RYGB leaks, 3 required reoperation versus 2 of 5 postrevision leaks. There were no perioperative deaths. All but 2 patients in the nonoperative group were treated with endoscopic injection of fibrin sealant (EIFS). Of the 4 leaks in the laparoscopic RYGB group, 2 treated by EIFS closed after 1 treatment; however, all leaks in the revision group required >1 EIFS treatment. The mean length of stay was 36 ± 34 days in the operative group and 33 ± 7 days in the EIFS patients. Operation for failure of EIFS was not required in any patient.

Conclusion: EIFS provides safe and successful treatment of patients who develop gastric leaks after bariatric operations. We recommend EIFS for all patients with endoscopically accessible leaks who can safely be treated nonoperatively.

Publication types

  • Evaluation Study
  • Multicenter Study

MeSH terms

  • Aged
  • Anastomotic Leak / drug therapy
  • Anastomotic Leak / surgery*
  • Female
  • Fibrin Tissue Adhesive / therapeutic use
  • Gastric Bypass / adverse effects*
  • Humans
  • Laparoscopy / adverse effects*
  • Length of Stay
  • Middle Aged
  • Obesity, Morbid / surgery*
  • Reoperation
  • Tissue Adhesives / therapeutic use

Substances

  • Fibrin Tissue Adhesive
  • Tissue Adhesives